NCT02935478 is a NA clinical trial of Embospheres Microspheres in Obesity, sponsored by St. Louis University.

Who is sponsoring NCT02935478?

NCT02935478 is sponsored by St. Louis University.

What drugs are being tested in NCT02935478?

Interventions in NCT02935478: Embospheres Microspheres.

What condition does NCT02935478 study?

NCT02935478 studies Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma, HCC, Hepatitis C, Cirrhosis.

Is NCT02935478 still recruiting?

NCT02935478 is currently suspended. Last updated 4 February 2025.

Last reviewed 2025-02-04 · How we verify

NCT02935478

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization in Obese Patients With Hepatocellular Carcinoma to Achieve Appropriate Weight Loss That May Allow Them to be Transplanted

Suspended NA Last updated 4 February 2025

What this trial tests

NA trial testing Embospheres Microspheres in Obesity in 8 participants. Suspended.

Timeline

18 October 2017

Primary endpoint
1 December 2026

1 December 2027

Quick facts

Lead sponsor	St. Louis University
Phase	NA
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	18 October 2017
Primary completion	1 December 2026
Estimated completion	1 December 2027
Sites	1 location across United States

Drugs / interventions tested

Embospheres Microspheres

Conditions studied

Obesity — all drugs for Obesity →
Weight Loss — all drugs for Weight Loss →
Body Weight — all drugs for Body Weight →
Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

St. Louis University

Who can join

Adults 18 to 65, any sex, with Obesity or Weight Loss. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Weight
Time frame: 12 months
Total body weight loss \> 10 % in 12 months

Sponsor's own description

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving them of the best option for cure from HCC. Recent studies have shown that blocking blood vessels to a particular portion of the stomach (bariatric or left gastric artery embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and result in weight loss.The purpose of this study is to determine if Left gastric artery embolization (LGAE) in patients with cirrhosis and HCC who are not transplant candidates due to morbid obesity, leads to clinically significant weight loss with eligibility for liver transplantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other St. Louis University trials

Trials by the same sponsor.

NCT07024940 — Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance · NA · recruiting
NCT06859528 — Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease · NA · recruiting
NCT04158037 — Don't Go There: A Geospatial mHealth App for Gambling Disorder · NA · withdrawn
NCT05406310 — Clinical Outcomes of Persistent Atrial Fibrillation Ablation Using Ablation Index-guided Radiofrequency Catheter Ablatio · withdrawn
NCT05854836 — Preconception Intervention for Incarcerated Women With Substance Use · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02935478 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Louis University
Last refreshed: 4 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02935478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing